Please login to the form below
companion diagnostic
This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.
Merck gets first approval for MET inhibitor tepotinib in Japan
The approval comes on the back of a phase 2 study – called VISION – which enrolled patients with METex14-positive NSCLC based on a just-approved companion diagnostic developed by genome analysis
Latest news
-
Roche and Illumina partner on genomics for cancer diagnostics
Roche will collaborate with Illumina to complement its comprehensive pan-cancer blood assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims. ... Building on the momentum of other recently established diagnostic and
-
Lynparza cleared for first-line ovarian cancer use in China
Around 22% of ovarian cancer patients carry a BRCA mutation (15% germline and 7% somatic), which must be identified via a companion diagnostic death.
-
GSK gets FDA okay for wider use of PARP drug Zejula
Zejula can be used in women who have been treated with three or more prior chemotherapy regimens and whose tumours are HRD-positive, identified using a just-approved companion diagnostic from ... In patients without BRCA mutations, but with a genomic
-
Roche undercuts price of Bayer cancer drug after winning FDA approval
Roche is working with Foundation Medicine to prepare a filing for FDA approval of the companion diagnostic, but for now no dedicated test is available. ... Vitrakvi also came to market without a companion diagnostic. Rozlytrek and Vitrakvi are part of a
-
Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund
Around 22% of ovarian cancer patients carry a BRCA mutation, which must be identified via a companion diagnostic test.
More from news
Approximately 1 fully matching, plus 61 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
The response has been a surge of interest in developing novel companion biomarkers, and biomarkers that allow personalisation of therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic
-
Drug launches to watch in 2019
At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to
-
Harnessing complexity
This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a
-
Diagnostics are rising up the pharma value chain
Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had
-
Deal Watch table for June 2014
50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new FoundationOne CDx, the first and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
